December 15, 2023 | Deborah Kotz
Contact
Deborah Kotz
Senior Director of Media Relations
Office of Public Affairs & Communications
University of Maryland School of Medicine
DKotz@som.umaryland.edu
o: 410-706-4255
c: 617-898-7955
t: @debkotz2
Related stories
Friday, December 08, 2023
UM School of Medicine Mourns the Loss of Dynamic Researcher, Chair, World Traveler, Giuseppe Inesi, MD
The University of Maryland School of Medicine mourns the loss of a dynamic researcher and teacher, Giuseppe Inesi, MD. He passed away on November 12 in Tiburon, California of Alzheimer’s disease.
Monday, July 24, 2023
Structure of Opioid Receptors May Reveal How to Better Design Pain Relievers, Addiction Therapies
Opioids remain the most potent and effective pain relievers in medicine, but they’re also among the most addictive drugs that can halt a person’s ability to breathe during an overdose — which can be deadly. Researchers have been racing to develop safer pain reliever drugs that target a specific opioid receptor, called the kappa opioid receptor, that is only found in the central nervous system and not elsewhere in the body, like other opioid receptors. Previous research suggests that such drugs may not lead to addiction or death due to overdose, but the currently known drugs that target these kappa opioid receptors have their own set of unacceptable side effects, including depression and psychosis.
Tuesday, September 26, 2017
University of Maryland Medicine Receives Prestigious Award For Its Heart and Lung Resuscitation Program
A heart and lung resuscitation program at University of Maryland Medicine (UMM) has been recognized for its elite level of care by a leading group in the field.
Monday, September 11, 2017
New Study Shows Novel Collaborative Intensive Care Can Significantly Improve Treatment for Heart Patients – and Cut Costs
Researchers at the University of Maryland School of Medicine (UM SOM) have found that a new, collaborative treatment model for seriously ill heart patients with breathing difficulties results in better care and lower costs.
Wednesday, June 07, 2017
University of Maryland School of Medicine Researchers Identify Gene That May Play a Central Role in Heart Disease
Heart disease kills more than 600,000 Americans every year, which translates to more than one in every four deaths. Although lifestyle choices contribute to the disease, genetics play a major role. This genetic facet has remained largely mysterious. But new research by scientists at the University of Maryland School of Medicine (UM SOM) has identified what may be a key player: a mutated gene that leads to irregular heartbeat, which can lead to a dangerously inefficient heart.
Friday, May 05, 2017
Secondhand Smoke Ups Heart Disease in Unique Group of Female Nonsmokers – Amish Women
New research at the University of Maryland School of Medicine (UM SOM) has found that secondhand smoke tends to have somewhat different effects on men and women. The research, conducted in a Pennsylvania Amish community where virtually no women smoke, found that women who were exposed to secondhand smoke had a greater risk for cardiovascular disease, while men exposed to secondhand smoke tended to have a higher body mass index (BMI).
Wednesday, January 11, 2017
University of Maryland Medical Center Offers Genetic Testing as Standard of Care to Help Improve Outcomes for Heart Stent Patients
The University of Maryland Medical Center (UMMC) is now offering a simple genetic test to patients who receive heart stents to determine whether they have a genetic deficiency that affects how they respond to a common drug to prevent blood clots. Patients are typically given the medication, clopidogrel, to prevent cardiovascular events after having a stent placed in a coronary artery to treat a blockage.
Tuesday, December 20, 2016
First U.S. Babies Treated in Unique Study of Adult Stem Cell Therapy for Congenital Heart Disease
In a first-in-children randomized clinical study, medical researchers at the University of Maryland School of Medicine (UM SOM) and the Interdisciplinary Stem Cell Institute (ISCI) at the University of Miami Miller School of Medicine have begun testing to see whether adult stem cells derived from bone marrow benefit children with the congenital heart defect hypoplastic left heart syndrome (HLHS).